Evidence map›Paper›PMID 31405112›Full record

ArticleInternational journal of molecular sciences2019

The Cyclooxigenase-2 Inhibitor Parecoxib Prevents Epidermal Dysplasia in HPV16-Transgenic Mice: Efficacy and Safety Observations.

Tiago Ferreira, Sandra Campos, Mónica G Silva, Rita Ribeiro, Susana Santos, José Almeida, Maria João Pires, Rui Miguel Gil da Costa, Cláudia Córdova, António Nogueira and 7 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. The Red SeaweedNutrients · 2021
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Tiago FerreiraDepartment of Veterinary Sciences, Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.
Sandra CamposDepartment of Veterinary Sciences, Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.
Mónica G SilvaCQVR, Chemistry Department, University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.
Rita RibeiroCQVR, Chemistry Department, University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.
Susana SantosDepartment of Veterinary Sciences, Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.
José AlmeidaDepartment of Veterinary Sciences, Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.
Maria João PiresDepartment of Veterinary Sciences, Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.
Rui Miguel Gil da CostaDepartment of Veterinary Sciences, Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.ORCID 0000-0002-2151-2449
Cláudia CórdovaSchool of Health Dr. Lopes Dias, IPC, 6000 Castelo Branco, Portugal.ORCID 0000-0002-2108-2629
António NogueiraMountain Research Centre (CIMO), IPB, 5300 Bragança, Portugal.
Maria João NeuparthAdvanced Polytechnic and University Cooperative (CESPU), Institute of Research and Advanced Training in Health Sciences and Technologies (IINFACTS), 4585 Gandra, Portugal.
Rui MedeirosMolecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), 4000 Porto, Portugal.
Margarida Maria da Silva Monteiro BastosMolecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), 4000 Porto, Portugal.
Isabel GaivãoDepartment of Genetics and Biotechnology and Animal and Veterinary Research Centre (CECAV), University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.
Francisco PeixotoCQVR, Biology and Environment Department, University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal.ORCID 0000-0001-9729-7477
Maria Manuel OliveiraCQVR, Chemistry Department, University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal. mmso@utad.pt.
Paula Alexandra OliveiraDepartment of Veterinary Sciences, Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5000 Vila Real, Portugal. pamo@utad.pt.ORCID 0000-0001-9519-4044
University of Trás-os-Montes and Alto Douro · PTFernando Pessoa University · PTInstituto Português de Oncologia Francisco Gentil · PTPolytechnic Institute of Bragança · PTPolytechnic Institute of Castelo Branco · PTUniversidade do Porto · PT

Funding

Portuguese Foundation for Science and Technology UID/AGR/04033/2019, UID/EQU/00511/2019; UID/CVT/00772/2019; LEPABE-2-ECO-INNOVATION" - NORTE-01-0145-FEDER-000005 and PEst-OE/QUI/UI0616/2014
6 · The paper itself

Abstract

Carcinogenesis induced by high-risk human papillomavirus (HPV) involves inflammatory phenomena, partially mediated by cyclooxigenase-2. In pre-clinical models of HPV-induced cancer, cyclooxygenase-2 inhibitors have shown significant efficacy, but also considerable toxicity. This study addresses the chemopreventive effect and hepatic toxicity of a specific cyclooxigensase-2 inhibitor, parecoxib, in HPV16-transgenic mice. Forty-three 20 weeks-old female mice were divided into four groups: I (HPV16

Indexed as

AnimalsAnticarcinogenic AgentsCyclooxygenase 2 InhibitorsFemaleHuman papillomavirus 16IsoxazolesMiceMice, TransgenicPapillomavirus InfectionsSkinSkin NeoplasmsAnticarcinogenic AgentsCyclooxygenase 2 InhibitorsIsoxazolesparecoxibCOX-2in vivoK14HPV16NSAID

Identifiers

PMID31405112
PMCPMC6720853
OpenAlexW2968793552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.